Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

SANUWAVE Issued U.S. Patent for a New Method to Produce Acoustic Shock Waves Utilizing Pressurized Fluid

January 18, 2012 By AxoGen, Inc.

ALPHARETTA, Ga.–(BUSINESS
WIRE
)–SANUWAVE Health, Inc. today announced that the U.S. Patent and
Trademark Office (USPTO) has issued the Company patent number 8,092,401, titled
“Method and Apparatus for Producing Shock Waves for Medical Applications.” The
patent has a term extending to February 2027 and relates to a new method of
producing shock waves utilizing a mechanically pressurized fluid.

In conventional methods to produce an acoustic shock wave,
the acoustic wave is triggered by an electrical impulse. By contrast, the novel
method presented in this patent is mechanical and comprises oscillating high
pressure generated in the encapsulated fluid within the treatment applicator,
which is used to produce focused acoustic shock waves. This innovation may
create efficiencies in design, manufacture and usability of the Companys
Pulsed Acoustic Cellular Expression (PACE®) technology and allows for unique
device configurations and clinical applications that were not previously
possible.

“We are pleased to be awarded this new patent as it has
potential to be a significant asset in our product development efforts,” stated
Christopher M. Cashman, President and CEO of SANUWAVE. “This method of
producing acoustic shock waves is different from the electrohydraulic method we
use in our current products, and it could give rise to new clinical indications
and alternative regulatory pathways for future product offerings.”

About PACE

PACE, defined as Pulsed Acoustic Cellular Expression, delivers high-energy
acoustic pressure waves in the shock wave spectrum to produce compressive and
tensile stresses on cells and tissue structures which are designed to promote
angiogenic and positive inflammatory responses, and quickly initiate the
healing cascade. This is thought to result in microcirculatory improvement,
including increased perfusion and blood vessel widening (arteriogenesis), the
production of angiogenic growth factors, enhanced new blood vessel formation
(angiogenesis) and the subsequent regeneration of tissue such as skin,
musculoskeletal and vascular structures. PACE procedures trigger the initiation
of an accelerated inflammatory response that speeds wounds into proliferation
phases of healing and subsequently returns a chronic condition to an acute
condition to help reinitiate the bodys own healing response.

About SANUWAVE Health, Inc.

SANUWAVE Health, Inc. (www.sanuwave.com) is an emerging regenerative medicine
company focused on the development and commercialization of noninvasive,
biological response activating devices for the repair and regeneration of
tissue, musculoskeletal and vascular structures. SANUWAVEs portfolio of
products and product candidates activate biologic signaling and angiogenic
responses, including new vascularization and microcirculatory improvement,
helping to restore the bodys normal healing processes and regeneration.
SANUWAVE intends to apply its PACE technology in wound healing,
orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product
candidate for the global wound care market, dermaPACE®, is CE marked for
treatment of the skin and subcutaneous soft tissue and recently completed its
pivotal Phase III, Investigational Device Exemption (IDE) clinical trial in the
U.S. for the treatment of diabetic foot ulcers. SANUWAVE researches, designs,
manufactures, markets and services its products worldwide, and believes it has
demonstrated that its technology is safe and effective in stimulating healing
in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral
epicondylitis) through its U.S. Class III PMA approved Ossatron® device, as
well as stimulating bone and chronic tendonitis regeneration in the
musculoskeletal environment through the utilization of its Ossatron, Evotron™
and orthoPACE® devices in Europe.

Posted by Sean Fenske, Editor-in-Chief, MDT

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech